Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing

Podobné jednotky

• Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
  Autor: Sullivan, Ivana, a další
  Vydáno: (2017)
• Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
  Autor: Westover, D, a další
  Vydáno: (2018)
• Update on third-generation EGFR tyrosine kinase inhibitors
  Autor: Gray, Jhanelle, a další
  Vydáno: (2014)
• Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma
  Autor: Kim, Hye Sook, a další
  Vydáno: (2013)
• Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence
  Autor: Wang, Xiaochun, a další
  Vydáno: (2016)